BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Closed|| Long (1Y)
Nirmal Bang recommends buy on Cipla
Cipla has received regulatory nod for launching Sereflo salmeterol/fluticasone MDI inhaler in the UK, which is generic equivalent of GlaxoSmithKline's (GSK's) Seretide evohaler, Nirmal Bang said. With the approval for Seroflo, there will be three players in the salmeterol/fluticasone MDI space in the UK, it added.